MedPath

Clinical Trial News

Endometrial Cancer Clinical Trial Landscape Shows Increasing Global Activity

  • A new report indicates a rise in endometrial cancer clinical trials globally, with the Asia-Pacific region experiencing the highest growth rate since 2014.
  • The United States and China lead in venture capital funding for endometrial cancer research, investing $2129 million and $894 million, respectively, between 2019 and 2023.
  • Clinical trials in North America and Asia-Pacific are focused on early to mid-phase studies, while Europe concentrates on later-stage trials for endometrial cancer.
  • Immunotherapies targeting Programmed Cell Death 1 Ligand 1 and Programmed Cell Death Protein 1 are prominent in Phase III trials for endometrial cancer.

Epilepsy Clinical Trial Landscape Shows Asia-Pacific Leading Research Activity

  • A recent report analyzes the global epilepsy clinical trial landscape, revealing over 4,000 trials initiated in the past 5 years, highlighting significant research efforts.
  • The Asia-Pacific region leads in epilepsy clinical trials, accounting for 35% of global activity, driven by shorter recruitment durations and faster rates.
  • Despite advancements, 50% of epilepsy cases have unknown causes, presenting ongoing challenges in treatment and management, spurring research into new therapies.
  • Venture capital funding for epilepsy research has shown a positive trend, with the United States leading investments, followed by Switzerland and China.

Global Liver Cancer Trial Landscape Shows Robust Activity in Asia-Pacific and North America

  • A new report reveals over 1,700 liver cancer trials initiated globally since 2018, highlighting significant investment in improving patient outcomes.
  • Asia-Pacific leads in trial volume, accounting for 55% of studies, followed by North America at 24%, indicating regional strengths in clinical research.
  • The hepatocellular carcinoma (HCC) treatment landscape is evolving, with diverse approaches including surgery, targeted therapies, and immunotherapies.
  • Funding for liver cancer research is substantial, particularly in the United States and China, supporting preclinical and early-phase clinical trials.

Global CLL Trial Landscape Shows Robust Activity, Highlights Regional Disparities

• A new report reveals that over 1,000 CLL clinical trials have been initiated globally since 2019, with North America leading at 37%, followed by Asia-Pacific at 34%. • CLL drug development includes 24 drugs in preclinical stages, 33 in Phase I, 30 in Phase II, and 4 in Phase III, with Bruton Tyrosine Kinase inhibitors dominating Phase III trials. • China led venture capital funding for CLL research from 2019 to 2023 with $1,813 million, closely followed by the United States with $1,805.6 million. • Targeted therapies, immunotherapy (CAR T-cell therapy), and precision medicine advancements have improved CLL treatment outcomes, with companies like AbbVie and BeiGene actively developing new therapies.

BMI Thresholds Impact Mortality Risk in NSCLC Immunotherapy vs. Chemotherapy

  • A study of over 500,000 lung cancer patients reveals that BMI affects mortality risk differently in immunotherapy versus chemotherapy.
  • For NSCLC patients with a BMI under 28, immunotherapy was associated with lower mortality compared to chemotherapy.
  • In patients with a BMI of 28 or higher, chemotherapy showed a continued decrease in mortality risk, while immunotherapy's risk increased.
  • Findings suggest BMI should be considered when selecting treatment for advanced non-small cell lung cancer.

Innate Pharma Advances Oncology Pipeline with Lacutamab, ANKET, and ADC Programs

  • Innate Pharma reported positive Phase 2 results for lacutamab in mycosis fungoides, engaging with the FDA for potential accelerated approval.
  • Sanofi's SAR443579/IPH6101, an ANKET-based NK cell engager, progressed to Phase 2, with a new Phase 1/2 combination study initiated in AML.
  • IPH45, Innate's Nectin-4 ADC, is advancing towards Phase 1 trials, demonstrating preclinical efficacy in enfortumab vedotin-refractory models.
  • Innate Pharma's cash position stands at €102.1 million, expected to fund operations through the end of 2025.

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

NCT06508489RecruitingPhase 1
Sanofi
Posted 8/13/2024

Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers

  • Sanofi, RadioMedix, and Orano Med have entered an exclusive licensing agreement to develop AlphaMedix for rare cancers, focusing on neuroendocrine tumors (NETs).
  • AlphaMedix, a targeted alpha therapy, has received FDA Breakthrough Therapy Designation for gastroenteropancreatic NETs in patients treatment-naive to peptide-receptor radionuclide therapy.
  • Clinical studies have shown AlphaMedix to be well-tolerated, providing substantial tumor reduction with a 62.5% durable response rate, supporting potential regulatory filing.
  • Sanofi will lead global commercialization, Orano Med will handle manufacturing, and RadioMedix and Orano Med will receive up to €320 million plus tiered royalties.

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

NCT05153772Active, Not RecruitingPhase 2
Orano Med LLC
Posted 12/21/2021

Immunovant's IMVT-1402 Shows Promise in Graves' Disease Treatment

  • Immunovant is launching a late-stage clinical trial for IMVT-1402, a novel anti-FcRn agent, offering a potential new treatment for Graves' disease.
  • IMVT-1402 targets the underlying cause of Graves' disease by blocking the recycling of IgG autoantibodies, which stimulate excess thyroid hormone production.
  • Phase 2 data with Immunovant's first-generation agent, batoclimab, showed meaningful response rates in treatment-resistant Graves' patients, exceeding 50%.
  • The global clinical trial aims to establish a geographically distributed network to enroll patients and assess the efficacy and safety of IMVT-1402.

Esophageal Cancer Clinical Trial Landscape Shows Surge in Global Research and Investment

  • A new report reveals over 1,530 esophageal cancer clinical trials initiated globally since 2019, with the Asia-Pacific region leading research efforts.
  • Esophageal cancer diagnoses are projected to increase by 80.5% by 2050, underscoring the urgent need for innovative treatments and improved patient outcomes.
  • Personalized medicine is gaining traction, with systemic therapies guided by molecular markers, and a robust pipeline of over 90 drugs in development.
  • China and the USA lead in funding esophageal cancer research, with investments of $2.9 billion and $2.1 billion USD, respectively, driving advancements in the field.

Evorpacept Shows Promise in HER2-Positive Gastric Cancer Treatment

  • ALX Oncology's Evorpacept, a CD47 inhibitor, demonstrates favorable results in Phase 2 trials for HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
  • Evorpacept, combined with trastuzumab, ramucirumab, and paclitaxel (TRP), shows comparable overall response rates to Enhertu in treating HER2-positive gastric cancer.
  • The Evorpacept plus TRP combination exhibits a longer median duration of response (15.7 months) compared to Enhertu (11.3 months) and TRP alone (7.6 months).
  • ALX Oncology's stock is currently undervalued, trading below its cash value, presenting a speculative buy opportunity with potential for significant returns if trials succeed.

Trending News

1

Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial

2 days ago
2

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

15 hours ago
3

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

a day ago
4

GH Research Submits IND Hold Response to FDA for Depression Treatment GH001 Ahead of Schedule

3 days ago
5

CanSinoBIO Launches iPneucia® 13-Valent Pneumococcal Vaccine Optimized for Chinese Children

3 days ago
6

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

14 hours ago
7

Bio-Thera Solutions Receives Positive CHMP Opinion for Ustekinumab Biosimilar USYMRO

3 days ago
8

Abvance Therapeutics Presents First Human Data on Fixed-Ratio Insulin-Glucagon Combination for Type 1 Diabetes

a day ago
9

ValiRx Secures £16 Million Licensing Deal for Repurposed Risperidone Cancer Therapy VAL401

3 days ago
10

Lomond Therapeutics Receives FDA Clearance for Phase 1 Trial of Lonitoclax in Relapsed/Refractory AML

3 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy